T 487

Drug Profile

T 487

Alternative Names: AMG-487; CXCR3 antagonists - Amgen

Latest Information Update: 02 Feb 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; ChemoCentryx
  • Class Anti-inflammatories; Pyrimidines; Small molecules
  • Mechanism of Action Chemokine receptor antagonists; CXCR3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 03 Jun 2005 No development reported - Phase-I for Rheumatoid arthritis (PO)
  • 17 Aug 2004 Tularik has been acquired and merged into Amgen
  • 12 Dec 2003 Phase-II clinical trials in Psoriasis in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top